GlassScriptPhysician profile
Saritha Ravella
NPI 1821244773
$2,695.17
in general payments reported to CMS, 2019-2025
37 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $54.59 · 2021: $261 · 2022: $123 · 2023: $124 · 2024: $802 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.77 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.13 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $237.62 | 2019-2024 | |
| Daiichi Sankyo INC. | $226.75 | 2020-2025 | Enhertu |
| Servier Pharmaceuticals LLC | $214.11 | 2021-2024 | |
| Genentech USA, INC. | $201.04 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Eisai INC. | $138.31 | 2022-2025 | |
| Seagen INC. | $135.88 | 2021-2022 | |
| Celgene Corporation | $127.10 | 2022-2025 | Reblozyl |
| Abbvie INC. | $108.27 | 2019-2025 | |
| Puma Biotechnology, INC. | $106.11 | 2019 | |
| Pfizer INC. | $104.83 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $83.71 | 2025 | Keytruda, Keytruda Qlex |
| Geron Corporation | $65.88 | 2025 | Rytelo |
| Lilly USA, LLC | $62.17 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Mirati Therapeutics, INC. | $50.48 | 2024 | Krazati |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saritha Ravella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.